Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO & EHA 2024 CLL Highlights
02 July 2024 | Virtual Meeting
Presentation summaries of key CLL abstracts from ASCO & EHA 2024 featuring panel discussions with leading experts
The Post-ASCO & EHA 2024 CLL Highlights was supported by Genentech, Lilly & Nurix. Supporters have no influence over the production of content.
Novel combinations with zanubrutinib
SEQUOIA: ZAN + VEN for TN CLL/SLL with del(17p) and/or tp53
Paolo Ghia Vita-Salute San Raffaele University, Milan, Italy
CELESTIAL-TNCLL: SONRO + ZANU vs VEN + OB for TN CLL
Piers Patten King's College London, London, United Kingdom
Session 1 panel discussion
Novel combinations with obinutuzumab
Pirtobrutinib + venetoclax + obinutuzumab in first-line CLL treatment
Nitin Jain The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Time-limited treatment with acala + obinutuzumab for TN CLL
Jan Burger The University of Texas MD Anderson Cancer Center, Houston, TX
Session 2 panel discussion
Novel BTK-based strategies & updates in bi-specifics
NX-5948 for R/R CLL and other B-cell malignancies
Alexey Danilov City of Hope, Duarte, CA, United States
BGB-16673-101: BGB-16673 in R/R CLL/SLL
Ricardo Parrondo Mayo Clinic, Jacksonville, FL, United States
AS-1763 in patients with previously treated B-cell malignancies
Nitin Jain The University of Texas MD Anderson Cancer Center, Houston, TX, United States
EPCORE CLL-1: epcoritamab for pts with Richter’s transformation
Arnon Kater University of Amsterdam, Amsterdam, Netherlands
Session 3 panel discussion
Long-term outcomes in CLL
7-year update on fixed-duration OB, IB, and VEN for CLL
Kerry Rogers The Ohio State University, Columbus, OH, United States
RESONATE-2: Up to 10 years of follow-up of IB for CLL/SLL
Jan Burger The University of Texas MD Anderson Cancer Center, Houston, TX
Session 4 panel discussion
Supported by:
Gold Supporters
Silver Supporters
